ZNF101 Inhibitors
Chemical inhibitors of ZNF101 can exert their inhibitory actions through various mechanisms by targeting signaling pathways and cellular processes that are crucial for the protein's functional activity. For instance, Chelerythrine and GF109203X, both Protein Kinase C inhibitors, can reduce the phosphorylation of proteins that ZNF101 may interact with. This results in a decrease in ZNF101's DNA-binding activity, as phosphorylation often regulates protein interactions and localization. Similarly, PD 98059 and U0126 specifically inhibit MEK1/2, leading to the suppression of ERK1/2 signaling. Since ERK1/2 is implicated in the regulation of various zinc finger proteins, the downstream effect includes a reduction in ZNF101 activity through prevented phosphorylation and subsequent activation. LY294002 and Wortmannin are phosphoinositide 3-kinases (PI3K) inhibitors, leading to diminished Akt signaling. Akt's role in modulating transcription factors implies that its inhibition could reduce the transcriptional activation capabilities of ZNF101.
In addition to these, SP600125 and SB203580 target the JNK and p38 MAP kinase pathways, respectively. By inhibiting these kinases, the chemical inhibitors can impair ZNF101's interaction with transcriptional machinery or its capacity for effective DNA binding. Y-27632, as a ROCK inhibitor, can alter cytoskeletal dynamics that may affect nuclear-cytoplasmic shuttling of regulatory molecules, potentially diminishing ZNF101's DNA-binding activity. Rapamycin inhibits mTOR, which is part of the PI3K/Akt pathway, and by doing so, could limit the availability of co-regulators necessary for ZNF101's function. Apigenin targets CK2, an enzyme that, when inhibited, impacts the phosphorylation state of proteins that co-regulate or modify ZNF101, thereby reducing ZNF101 activity. Lastly, Triptolide inhibits the transcriptional activity by affecting the RNA polymerase II machinery, upon which ZNF101's transcription factor activity is dependent, thus inhibiting the function of ZNF101 by hindering the transcription process it is designed to regulate.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is known to inhibit Protein Kinase C (PKC), which could decrease the phosphorylation of proteins that ZNF101 may interact with, leading to a reduction in ZNF101's DNA-binding activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an inhibitor of MEK, which in turn inhibits ERK1/2 signaling. ERK1/2 has been implicated in the regulation of various zinc finger proteins. Inhibition of this pathway could reduce ZNF101 activity by preventing its phosphorylation and activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which would lead to decreased Akt signaling. Since Akt can modulate various transcription factors and nuclear proteins, inhibiting this pathway might reduce the functional activity of ZNF101 through reduced transcriptional activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. JNK pathway is involved in the regulation of numerous transcription factors. Inhibition of JNK signaling may impair ZNF101's interaction with other transcriptional machinery or its ability to bind DNA effectively. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor, which could lead to altered transcription factor dynamics. Inhibition of p38 MAPK might prevent the activation or nuclear translocation of factors that co-regulate ZNF101 target genes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, similar to LY294002, and would also result in decreased Akt activity. This could lower the activity of ZNF101 by affecting the transcription factor networks in which it operates. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor, which could alter the cytoskeletal dynamics and thereby potentially affect the nuclear-cytoplasmic shuttling of molecules that regulate ZNF101's DNA-binding activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, similar to PD 98059. By inhibiting MEK1/2, it would also inhibit ERK1/2 signaling, which may be required for the full activity of ZNF101 by affecting its phosphorylation status. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
GF109203X is another PKC inhibitor, which could prevent the phosphorylation of proteins that interact with ZNF101, thereby inhibiting ZNF101's function in gene regulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is part of the PI3K/Akt pathway. Downregulation of mTOR activity can lead to reduced protein synthesis and may limit the availability of co-regulators necessary for ZNF101 activity. | ||||||